Recurrent infection of continuous subcutaneous insulin infusion sites with Mycobacterium fortuitum.
Toth
E L
EL
Department of Medicine, University of Alberta, Edmonton, Canada. ellen@medi.dmed.ualberta.ca
Boychuk
L R
LR
Kirkland
P A
PA
D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D001786:Blood Glucose / Q000378:metabolism; D002440:Cefoxitin / Q000627:therapeutic use; D002939:Ciprofloxacin / Q000627:therapeutic use; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy*; D004359:Drug Therapy, Combination / Q000627:therapeutic use; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D007279:Injections, Subcutaneous / Q000009:adverse effects*; D007328:Insulin / Q000008:administration & dosage / Q000627:therapeutic use*; D008911:Minocycline / Q000009:adverse effects / Q000627:therapeutic use; D009164:Mycobacterium Infections / Q000188:drug therapy / Q000209:etiology* / Q000601:surgery; D012008:Recurrence
D000900:Anti-Bacterial Agents; D001786:Blood Glucose; D002440:Cefoxitin; D002939:Ciprofloxacin; D006442:Glycated Hemoglobin; D007328:Insulin; D008911:Minocycline